Draft:Jamal Tazi
| Submission declined on 14 May 2025 by Ldm1954 (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
| Submission declined on 7 May 2025 by Scope creep (talk). A complete mess. Declined by Scope creep 14 days ago. | |
| Submission declined on 28 April 2025 by Bonadea (talk). Your draft shows signs of having been generated by a large language model, such as ChatGPT. Their outputs usually have multiple issues that prevent them from meeting our guidelines on writing articles. These include: Declined by Bonadea 22 days ago.
| |
| Submission declined on 27 April 2025 by Theroadislong (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia. Declined by Theroadislong 23 days ago. | |
Comment: pointless re-submitting with zero improvement. Theroadislong (talk) 11:33, 29 April 2025 (UTC)
- Comment: In accordance with Wikipedia's Conflict of interest policy, I disclose that I have a conflict of interest regarding the subject of this article. Jamal Tazi (talk) 21:09, 27 April 2025 (UTC)
Jamal Tazi | |
|---|---|
| Born | 1959 Rabat, Morocco |
| Nationality | French, Moroccan |
| Alma mater | University of Montpellier |
| Known for | RNA metabolism, Alternative splicing, RNA-based therapies |
| Scientific career | |
| Fields | Molecular biology, Biotechnology |
| Institutions | University of Montpellier, CNRS, Abivax |
Jamal Tazi (born 1959 in Rabat, Morocco) is a Franco-Moroccan molecular biologist and biotechnology entrepreneur. He is a professor at the University of Montpellier, specializing in RNA metabolism, alternative splicing, and RNA-based therapeutic strategies.
Education
[edit]Tazi obtained a Ph.D. in molecular and cellular biology in France in 1988 at the University of Montpellier.[1][irrelevant citation] He conducted postdoctoral research from 1988 to 1990 at the Institute of Molecular Pathology (IMP) in Vienna, Austria, where he studied chromatin structure and the regulation of CpG islands.[2][irrelevant citation]
Academic career
[edit]In 1990, Tazi joined the French National Centre for Scientific Research (CNRS) as a junior scientist and was promoted to senior scientist in 1993.[3][irrelevant citation] In 1996, he established a research group at the Institute of Molecular Genetics of Montpellier (IGMM), focusing on the regulation of RNA metabolism, particularly alternative splicing during cell proliferation, differentiation, and development.[4][irrelevant citation]
In 2005, he was appointed full professor at the University of Montpellier.[1]
Entrepreneurship and Industry Contributions
[edit]In a 2007 interview with Futura Sciences, Tazi discussed the development of IDC-16, a molecule aimed at inhibiting HIV replication by interfering with the virus's use of cellular processes.[5]
In 2014, Tazi co-founded Abivax, a biopharmaceutical company developing therapies for inflammatory and infectious diseases, and became Vice President of Research from 2019 to 2024.[6]
Research conducted at Abivax led to the development of ABX464, a molecule investigated for its potential in HIV treatment. According to 20 Minutes, ABX464 was described as "a molecule that could revolutionize HIV treatment."[7][failed verification]
Tazi contributed to research identifying ABX464’s mechanism of action, including the induction of the anti-inflammatory microRNA miR-124.[8][9] The molecule, later renamed obefazimod, advanced to Phase III clinical trials for the treatment of ulcerative colitis and is being evaluated for other chronic inflammatory diseases.[10]
Public Recognition and Media Appearances
[edit]Tazi appeared on the France 24 program Daif wa Massira, where he discussed his research and career.[11] His scientific work has been featured in media outlets such as France TV Info,[9] Le Matin,[12] H24 Info,[13] and Midi Libre.[14] He is also listed in Who's Who in France and Who's Who Worldwide.[15]
Scientific Contributions
[edit]Tazi has authored over 151 peer-reviewed scientific publications and contributed to several book chapters.[16] As of 2025, his work has achieved an H-index of 45.[16] He holds or co-holds 26 patents related to RNA biology and therapeutic applications.[17]
Awards and Honors
[edit]- 1999: Prize of the French Academy of Sciences for research in molecular biology.[18]
- 2006: Prize of the French Academy of Medicine.[19]
- 2009: ARRI Award for French Influence.[20]
- 2017: CNRS Medal for Innovation.[21]
Teaching and Training
[edit]Tazi has supervised 27 doctoral theses and organized several advanced training courses and conferences in molecular biology and RNA therapeutics.[1]
References
[edit]- ^ a b c "Université de Montpellier". https://www.umontpellier.fr (in French). Retrieved 2025-05-14.
{{cite web}}: External link in|website= - ^ Pathology, Research Institute of Molecular. "Research Institute of Molecular Pathology (IMP) | Molecular Biology at Vienna BioCenter". The Research Institute of Molecular Pathology. Retrieved 2025-05-14.
- ^ "Centre national de la recherche scientifique (CNRS)". www.cnrs.fr (in French). 2025-05-13. Retrieved 2025-05-14.
- ^ "IGMM – Institut de Génétique Moléculaire de Montpellier" (in French). Retrieved 2025-05-14.
- ^ "Podcast : l'espoir d'une nouvelle arme anti-Sida". Futura Sciences. 9 November 2007. Retrieved 29 April 2025.
- ^ Abivax. "About Us." Retrieved April 28, 2025, from [1]
- ^ "Montpellier: ABX464, a molecule that could revolutionize HIV treatment." 20 Minutes. 14 February 2017. Retrieved April 28, 2025.
- ^ Drug Discovery Today. "Discovery and development of obefazimod as an anti-inflammatory agent." Retrieved April 28, 2025, from [2]
- ^ a b "A new way to block HIV virus replication." France TV Info. 24 February 2016. Retrieved April 28, 2025.
- ^ "Montpellier: Jamal Tazi awarded the CNRS Innovation Medal." Actu.fr. 13 June 2017. Retrieved April 28, 2025.
- ^ "Interview with Professor Jamal Tazi." France 24 - Daif wa Massira. 15 February 2023. Retrieved April 28, 2025.
- ^ "Jamal Tazi develops a new weapon against HIV." Le Matin. 3 May 2017. Retrieved April 28, 2025.
- ^ "Moroccan researcher invents a molecule to neutralize HIV." H24 Info. 4 May 2017. Retrieved April 28, 2025.
- ^ "A new molecule discovered in Montpellier to fight HIV." Midi Libre. 20 April 2015. Retrieved April 28, 2025.
- ^ Entry in Who's Who in France.
- ^ a b Jamal Tazi. ORCID Profile. Retrieved April 28, 2025, from [3]
- ^ Jamal Tazi Patents. Justia Patents. Retrieved April 28, 2025, from [4]
- ^ French Academy of Sciences. "Prize Winners." Retrieved April 28, 2025, from [5]
- ^ French Academy of Medicine. "Awards." Retrieved April 28, 2025, from [6]
- ^ Association ARRI. "Award Recipients." Retrieved April 28, 2025, from [7]
- ^ CNRS News. "Laureates of the CNRS Medal of Innovation 2017." Retrieved April 28, 2025, from [8]